Industry Standard Research
(ISR) today announced the release of a new market research report titled “
EDC and ePRO Market Trends and Service Provider Performance
.” This report provides the pharmaceutical industry and its service providers with novel insights into the current and future use of these technologies and enables better technology provider selection.
“From a classical market development point of view, EDC technology has finally ‘crossed the chasm’ and has become the de facto data collection mechanism for clinical trials,” Andrew Schafer, President of ISR explained. “While ePRO does not start from the same vantage point – not all studies need a patient-reported outcome component – we do see the ePRO market maturing and several products beginning to emerge as market leaders.”
ISR’s study surveyed 101 site-coordinators and principal investigators with responsibility for data collection at their sites. The data ISR captured represent 710 on-the-ground service experiences across 20 EDC and 14 ePRO products.
“With this data, sponsors can make more informed outsourcing decisions, improve relationships with sites by utilizing technology platforms they prefer, and build efficiencies into study designs,” Schafer explained. “For service providers, this ‘Voice-of-the-Customer’ research offers unique product satisfaction data from end-users on their product and their competitors.”
In addition to end-user satisfaction data, ISR’s report also provides service providers with important insights into current and future EDC and ePRO market trends, including: adoption, usage, preference, study penetration by Phase, and the new ‘eClinical’ service many large CROs are beginning to offer that is sure to impact the competitive landscape.
For more information about ISR’s report, please visit its website
here
.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.